PT - JOURNAL ARTICLE AU - Jamieson, Lise AU - Rosen, Sydney AU - Phiri, Bevis AU - Grimsrud, Anna AU - Mwansa, Muya AU - Shakwelele, Hilda AU - Haimbe, Prudence AU - Mwenechanya, Mpande M AU - Lumano-Mulenga, Priscilla AU - Chimboma, Innocent AU - Nichols, Brooke E TI - How soon should patients be eligible for differentiated service delivery models for antiretroviral treatment? Evidence from Zambia AID - 10.1101/2021.08.25.21262587 DP - 2022 Jan 01 TA - medRxiv PG - 2021.08.25.21262587 4099 - http://medrxiv.org/content/early/2022/03/13/2021.08.25.21262587.short 4100 - http://medrxiv.org/content/early/2022/03/13/2021.08.25.21262587.full AB - Introduction Attrition from HIV treatment is high during patients’ first 6 months after antiretroviral therapy (ART) initiation and patients with less than 6 months on ART are systematically excluded from most differentiated service delivery (DSD) models, which are intended to reduce attrition. Despite eligibility criteria requiring greater than 6 months on ART, some patients enroll earlier. Using routinely-collected medical record data in Zambia, we compared loss to follow-up (LTFU) among patients enrolling in DSD models early (<6 months on ART) to LTFU among those who enrolled according to guidelines (≥6 months on ART) in order to assess whether the ART experience eligibility criterion is necessary.Methods We extracted data from electronic medical records for adults (≥15 years) who initiated ART between 01/01/2019 and 31/12/2019 and evaluated LTFU, defined as >90 days late for last scheduled medication pickup, at 18 months for “early enrollers” (DSD enrolment after <6 months on ART) and “established enrollers” (DSD enrolment after ≥6 months on ART). We used a log-binomial model to compare LTFU risk between groups, adjusting for age, sex, urban/rural status, ART refill interval and DSD model.Results For 6,340 early enrollers and 25,857 established enrollers there were no important differences between the groups in sex (61% female), age (median 37 years), or setting (65% urban). ART refill intervals were longer for established vs early enrollers (72% vs 55% were given 4–6-month refills). LTFU at 18 months was 3% (192/6,340) for early enrollers and 5% (24,646/25,857) for established enrollers. Early enrollers were 41% less likely to be LTFU than established patients (adjusted risk ratio [95% confidence interval] 0.59 [0.50-0.68]).Conclusions Patients enrolled in DSD models in Zambia with < 6 months on ART were more likely to be retained in care than patients referred after they were established on ART. A limitation of the analysis is that early enrollers may have been selected for DSD participation due to providers’ and patients’ expectations about future retention. Offering DSD model entry to at least some ART patients <6 months after ART initiation may help address high attrition during the early treatment period.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for the study was provided by the Bill & Melinda Gates Foundation through OPP1192640 to Boston University. The funder had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study protocol was approved by ERES Converge IRB (Zambia), protocol number 2019-Sep-030, the Human Research Ethics Committee (Medical) of the University of Witwatersrand, protocol number M190453, and the Boston University IRB H-38823 for the use of data with a waiver of consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data were obtained from Zambia's national electronic medical record system. Derived data supporting the findings of this study are available from the corresponding author [BEN] on request.